Alvotech’s Eylea Biosimilar ‘Keeps In Mind’ US Patent Landscape
Icelandic Firm Sees ‘Very Interesting Opportunity’ But Will Not Commit To Instant Launch
Alvotech will consider its options upon the potential US approval of its proposed biosimilar to Eylea, though the firm maintains that its formulation has been developed with the patent landscape in mind.
